⏳ Fetching live dividend data...
Home › Calculator › LJPC Dividend Calculator 2026
La Jolla Pharmaceutical Company · NASDAQ
Price: $6.19 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in LJPC → $13.92M in 10 years · $365.83/month
La Jolla Pharmaceutical Company is dedicated to the creation and marketing of therapeutic solutions, with the ultimate goal of enhancing patient outcomes in the face of life-threatening illnesses. The company's commercialized offerings include GIAPREZA, a potent vasoconstrictor designed to raise blood pressure in adult patients afflicted by septic or other forms of distributive shock. Additionally, it provides XERAVA, a tetracycline-class antibacterial effective in treating complex intra-abdominal infections in individuals aged 18 and above. These vital medications are supplied to hospitals and other healthcare institutions exclusively within the United States. Looking ahead, La Jolla is actively advancing several investigational drug candidates through early-stage clinical or preclinical development. These encompass TP-6076, an intravenous fluorocycline derivative targeting specific multidrug-resistant gram-negative bacteria; TP-271, a fluorocycline available for both intravenous and oral administration, intended to address respiratory conditions stemming from bacterial biothreats, antibiotic-resistant public health pathogens, and community-acquired bacterial pneumonia; and TP-2846, an intravenous tetracycline being explored for its potential in treating acute myeloid leukemia. The company has forged key strategic partnerships, including a licensing agreement with Everest Medicines Limited for the development and commercialization of XERAVA. Furthermore, it holds a similar agreement with PAION AG for the commercialization of both GIAPREZA and XERAVA. Founded in 1989 and headquartered in Waltham, Massachusetts, La Jolla Pharmaceutical Company has operated as a subsidiary of Innoviva, Inc. since August 22, 2022.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open LJPC position with:
Real after-tax yield depends on where you live and how you hold LJPC.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 32.31% | 29.51% | $3,231 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 27.46% | 24.66% | $2,746 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 25.85% | 23.05% | $2,585 / yr |
| 🇬🇧 UK ISA | 0% | 32.31% | 29.51% | $3,231 / yr |
| 🇬🇧 UK Taxable | 8.75% | 29.48% | 26.68% | $2,948 / yr |
| 🇨🇦 TFSA | 0% | 32.31% | 29.51% | $3,231 / yr |
| 🇨🇦 CA Taxable | 25% | 24.23% | 21.43% | $2,423 / yr |
| 🇦🇺 Super (pension) | 15% | 27.46% | 24.66% | $2,746 / yr |
| 🇦🇺 AU Taxable | 30% | 22.62% | 19.82% | $2,262 / yr |
| 🇩🇪 DE Taxable | 26.375% | 23.79% | 20.99% | $2,379 / yr |
| 🇫🇷 FR Taxable | 30% | 22.62% | 19.82% | $2,262 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
LJPC pays quarterly — 4 times per year. Next ex-div: TBD.
How LJPC compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for LJPC sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2022-08-22 | 30,000 | — | — | ||
| D-Return | 2022-08-22 | 10,000 | $28.24 | $282.4K | ||
| D-Return | 2022-08-22 | 10,000 | $19.19 | $191.9K | ||
| D-Return | 2022-08-22 | 12,000 | $5.99 | $71.9K | ||
| D-Return | 2022-08-22 | 18,000 | $8.52 | $153.4K | ||
| D-Return | 2022-08-22 | 12,000 | $3.93 | $47.2K | ||
| D-Return | 2022-08-22 | 30,000 | $4.53 | $135.9K | ||
| D-Return | 2022-08-22 | 30,000 | $4.81 | $144.3K | ||
| D-Return | 2022-08-22 | 10,000 | $28.10 | $281.0K | ||
| D-Return | 2022-08-22 | 10,000 | $19.69 | $196.9K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the LJPC dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
La Jolla Pharmaceutical Company (LJPC) is currently trading at $6.19, trading near its 52-week high. The current dividend yield is 32.31% based on an annual payout of $2.00 per share.
La Jolla Pharmaceutical Company (LJPC) is a healthcare stock currently trading at $6.19 with a dividend yield of 32.31%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever